- Home
- TCRX vs IPHA Comparison
TCRX vs IPHA Comparison
Compare TCRX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- IPHA
- Stock Information
- Founded
- TCRX 2018
- IPHA 1999
- Country
- TCRX United States
- IPHA France
- Employees
- TCRX N/A
- IPHA N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- IPHA Health Care
- Exchange
- TCRX Nasdaq
- IPHA Nasdaq
- Market Cap
- TCRX 140.7M
- IPHA 160.1M
- IPO Year
- TCRX 2021
- IPHA 2019
- Fundamental
- Price
- TCRX $1.89
- IPHA $1.98
- Analyst Decision
- TCRX Strong Buy
- IPHA Strong Buy
- Analyst Count
- TCRX 5
- IPHA 3
- Target Price
- TCRX $9.40
- IPHA $5.00
- AVG Volume (30 Days)
- TCRX 656.4K
- IPHA 22.9K
- Earning Date
- TCRX 11-07-2025
- IPHA 09-17-2025
- Dividend Yield
- TCRX N/A
- IPHA N/A
- EPS Growth
- TCRX N/A
- IPHA N/A
- EPS
- TCRX N/A
- IPHA N/A
- Revenue
- TCRX $6,961,000.00
- IPHA $14,839,695.00
- Revenue This Year
- TCRX $255.18
- IPHA $50.89
- Revenue Next Year
- TCRX N/A
- IPHA N/A
- P/E Ratio
- TCRX N/A
- IPHA N/A
- Revenue Growth
- TCRX N/A
- IPHA N/A
- 52 Week Low
- TCRX $1.02
- IPHA $1.29
- 52 Week High
- TCRX $6.23
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- TCRX 39.56
- IPHA 45.26
- Support Level
- TCRX $1.74
- IPHA $1.95
- Resistance Level
- TCRX $2.43
- IPHA $2.40
- Average True Range (ATR)
- TCRX 0.18
- IPHA 0.12
- MACD
- TCRX -0.07
- IPHA -0.01
- Stochastic Oscillator
- TCRX 14.46
- IPHA 6.67
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.